- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
The consolidated financials indicate that Hester Biosciences has reaffirmed its credit ratings, maintaining a CARE BBB+ with a stable outlook for long-term bank facilities. This reflects a steady operational and financial performance, especially within FY24 and H1FY25.
Total long-term bank facilities stand at ₹95.18 crore, reduced from ₹122.28 crore, while long-term/short-term facilities are ₹65.00 crore and short-term at ₹0.22 crore. The reduction in long-term facilities suggests a strategic shift towards better debt management and cost efficiency.
The current rating signals a stable financial condition, supported by consistent revenue streams and moderate debt levels. The stable outlook indicates that CARE Ratings expects no major negative shifts in financial health.
The reaffirmation of these ratings could maintain favorable borrowing costs for the company, assisting in future strategic investments or operational expansions. Investor sentiment is likely to remain positive given the stable ratings and prudent financial management.
Based on this analysis, investors may consider holding their positions as the financial outlook remains stable, with opportunities for growth amid prudent risk management.